GOODMAN AND GILMAN'S THE
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
1
Reference
Ch. 1 — Natural products & lead identification
Stem
A small biotech has identified a plant-derived alkaloid with
moderate inhibition of a GPCR implicated in neuropathic pain.
The compound has poor oral bioavailability, high first-pass
hepatic clearance in rats, and a hydroxyl group believed
essential for receptor binding. As a translational pharmacologist
,advising lead optimization, which strategy best balances
retaining affinity while improving oral exposure for first-in-
human studies?
A. Replace the hydroxyl with a methoxy group to reduce phase
II conjugation and improve permeability.
B. Design an ester prodrug masking the hydroxyl to increase
permeability, expecting rapid plasma conversion to the active
parent.
C. Increase lipophilicity by adding a bulky aromatic substituent
distal to the pharmacophore to reduce clearance.
D. Abandon the scaffold and screen for non-natural synthetic
analogs with different polar groups.
Correct answer
B
Rationale — Correct (B)
An ester prodrug masking the essential hydroxyl can improve
membrane permeability and oral absorption while allowing
enzymatic hydrolysis in plasma or tissues to regenerate the
pharmacophore. This approach preserves the necessary
hydroxyl for receptor binding after conversion, directly
addressing first-pass and permeability issues in a pragmatic
translational path. Prodrug design is a common, efficient
strategy during lead optimization when a functional group is
required for activity.
Rationale — Incorrect
A. Methoxy substitution may reduce conjugation but often
,abolishes hydrogen-bonding interactions required for receptor
affinity; it risks losing potency.
C. Increasing lipophilicity arbitrarily can reduce clearance in
some cases but often increases non-specific binding, toxicity,
and decreases solubility—poor risk/benefit for first-in-human.
D. Abandoning the scaffold discards known activity and adds
time/cost; unnecessary if targeted medicinal chemistry can
address ADME.
Teaching point
Prodrugs mask essential polar groups to improve absorption
while regenerating active drug in vivo.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
2
Reference
Ch. 1 — Target validation & genetic tools
Stem
A novel protein is proposed as a target for a kinase inhibitor to
treat an aggressive cancer. CRISPR knockout in tumor cell lines
reduces proliferation, but germline knockout in mice causes
embryonic lethality. Which interpretation most accurately
informs go/no-go target validation for small-molecule
development?
, A. The embryonic lethality means the target is undruggable due
to essential physiology; development should stop.
B. CRISPR knockout effects in tumor cells validate on-target
anticancer potential; embryonic lethality indicates likely on-
target toxicity risk to evaluate.
C. The embryonic phenotype invalidates the CRISPR tumor-line
findings because gene function differs across tissues.
D. Proceed to high-throughput screening without concern—the
cellular model is the only relevant validation for cancer therapy.
Correct answer
B
Rationale — Correct (B)
Tumor-cell CRISPR knockout shows on-target anticancer
efficacy, supporting the target for oncology. Embryonic lethality
warns of essential roles in development and potential systemic
toxicity—critical for risk assessment and designing therapeutics
(e.g., tumor-selective delivery, transient inhibition, or allosteric
modulation). Both data points should shape a development
strategy rather than an outright stop.
Rationale — Incorrect
A. Embryonic lethality does not automatically make a target
undruggable; mitigation strategies and context-dependent
targeting are possible.
C. Tissue-specific functions can vary, but the two data sources
are complementary rather than contradictory—this option
dismisses important safety information.
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
1
Reference
Ch. 1 — Natural products & lead identification
Stem
A small biotech has identified a plant-derived alkaloid with
moderate inhibition of a GPCR implicated in neuropathic pain.
The compound has poor oral bioavailability, high first-pass
hepatic clearance in rats, and a hydroxyl group believed
essential for receptor binding. As a translational pharmacologist
,advising lead optimization, which strategy best balances
retaining affinity while improving oral exposure for first-in-
human studies?
A. Replace the hydroxyl with a methoxy group to reduce phase
II conjugation and improve permeability.
B. Design an ester prodrug masking the hydroxyl to increase
permeability, expecting rapid plasma conversion to the active
parent.
C. Increase lipophilicity by adding a bulky aromatic substituent
distal to the pharmacophore to reduce clearance.
D. Abandon the scaffold and screen for non-natural synthetic
analogs with different polar groups.
Correct answer
B
Rationale — Correct (B)
An ester prodrug masking the essential hydroxyl can improve
membrane permeability and oral absorption while allowing
enzymatic hydrolysis in plasma or tissues to regenerate the
pharmacophore. This approach preserves the necessary
hydroxyl for receptor binding after conversion, directly
addressing first-pass and permeability issues in a pragmatic
translational path. Prodrug design is a common, efficient
strategy during lead optimization when a functional group is
required for activity.
Rationale — Incorrect
A. Methoxy substitution may reduce conjugation but often
,abolishes hydrogen-bonding interactions required for receptor
affinity; it risks losing potency.
C. Increasing lipophilicity arbitrarily can reduce clearance in
some cases but often increases non-specific binding, toxicity,
and decreases solubility—poor risk/benefit for first-in-human.
D. Abandoning the scaffold discards known activity and adds
time/cost; unnecessary if targeted medicinal chemistry can
address ADME.
Teaching point
Prodrugs mask essential polar groups to improve absorption
while regenerating active drug in vivo.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
2
Reference
Ch. 1 — Target validation & genetic tools
Stem
A novel protein is proposed as a target for a kinase inhibitor to
treat an aggressive cancer. CRISPR knockout in tumor cell lines
reduces proliferation, but germline knockout in mice causes
embryonic lethality. Which interpretation most accurately
informs go/no-go target validation for small-molecule
development?
, A. The embryonic lethality means the target is undruggable due
to essential physiology; development should stop.
B. CRISPR knockout effects in tumor cells validate on-target
anticancer potential; embryonic lethality indicates likely on-
target toxicity risk to evaluate.
C. The embryonic phenotype invalidates the CRISPR tumor-line
findings because gene function differs across tissues.
D. Proceed to high-throughput screening without concern—the
cellular model is the only relevant validation for cancer therapy.
Correct answer
B
Rationale — Correct (B)
Tumor-cell CRISPR knockout shows on-target anticancer
efficacy, supporting the target for oncology. Embryonic lethality
warns of essential roles in development and potential systemic
toxicity—critical for risk assessment and designing therapeutics
(e.g., tumor-selective delivery, transient inhibition, or allosteric
modulation). Both data points should shape a development
strategy rather than an outright stop.
Rationale — Incorrect
A. Embryonic lethality does not automatically make a target
undruggable; mitigation strategies and context-dependent
targeting are possible.
C. Tissue-specific functions can vary, but the two data sources
are complementary rather than contradictory—this option
dismisses important safety information.
